- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.08. | ImageneBio, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 01.08. | ImageneBio: Vorstand genehmigt Anreizplan 2025 zur Mitarbeitergewinnung | 2 | Investing.com Deutsch | ||
| 01.08. | ImageneBio, Inc.: ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 97 | GlobeNewswire (Europe) | SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("ImageneBio"), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune and... ► Artikel lesen | |
| 29.07. | ImageneBio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.07. | Ikena Oncology, Inc.: Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million | 226 | GlobeNewswire (Europe) | The combined company will operate under the name "ImageneBio, Inc." and will begin trading on Nasdaq under the ticker symbol "IMA" at market open on Monday, July 28, 2025 ImageneBio, Inc. will... ► Artikel lesen | |
| 24.07. | Ikena Oncology, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 23.07. | Ikena Oncology stock rises after naming Kristin Yarema as CEO of combined company | 1 | Investing.com | ||
| 23.07. | Ikena Oncology, Inmagene Biopharmaceuticals appoint Kristin Yarema, as CEO | 1 | Seeking Alpha | ||
| IMAGENEBIO Aktie jetzt für 0€ handeln | |||||
| 23.07. | Ikena Oncology and Inmagene name Kristin Yarema as CEO of combined firm | 5 | Investing.com | ||
| 23.07. | Ikena Oncology, Inc.: Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company | 202 | GlobeNewswire (Europe) | BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema... ► Artikel lesen | |
| 22.07. | Ikena Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.07. | Ikena Oncology ändert Vergütungsvereinbarung für Dr. Jotin Marango vor Fusion | 1 | Investing.com Deutsch | ||
| 15.07. | Ikena Oncology, Inc.: Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals | 172 | GlobeNewswire (Europe) | Combined Company to Trade on Nasdaq Under Ticker "IMA" Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock BOSTON and SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc.... ► Artikel lesen | |
| 12.07. | ISS And Glass Lewis Support Ikena Oncology's Share Issuance For Proposed Inmagene Merger | 5 | RTTNews | ||
| 11.07. | Ikena Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.07. | Ikena Oncology, Inc.: Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote "FOR" Proposed Merger with Inmagene Biopharmaceuticals | 105 | GlobeNewswire (Europe) | BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, "Ikena," the "Company") today announced that Institutional Shareholder Services Inc. ("ISS") and Glass, Lewis & Co. ("Glass... ► Artikel lesen | |
| 01.07. | Ikena Oncology, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 09.06. | Ikena Oncology, Inc. - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
| 30.05. | Ikena Oncology, Inc. - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
| 20.05. | Ikena Oncology, Inc. - S-4/A, Registration of securities, business combinations | 2 | SEC Filings |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,072 | +1,20 % | Die Blaupause für KI-Medikamentenentwicklung: So nutzen Evotec, NetraMark Holdings und BioNTech die neuen Möglichkeiten | Die Pharmabranche befindet sich mitten in einer Revolution. Künstliche Intelligenz verkürzt die Wirkstoffentwicklung von Jahren auf Monate und steigert die Trefferquote dramatisch. Datengetriebene Prognosen... ► Artikel lesen | |
| BIOGEN | 114,75 | -0,35 % | Aktie von Biogen: Kurs mit wenig Bewegung (117,3477 €) | Der Kurs der der Biogen-Aktie kommt kaum von der Stelle. Zuletzt zahlten Investoren für das Wertpapier 136,50 US-Dollar. Der Kurs der Aktie von Biogen zeigt sich zur Stunde kaum verändert im Vergleich... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | - | - | Boehringer Ingelheim Limited: Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases | · Collaboration strengthens Boehringer's pipeline in Eye Health.· Many patients with diabetic retinopathy (DR) continue to experience vision loss or treatment fatigue, underscoring an... ► Artikel lesen | |
| MAINZ BIOMED | 1,655 | +0,30 % | Mainz BioMed NV: Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert | BERKELEY, Calif. and MAINZ, Germany, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,000 | -0,56 % | Why Viking Therapeutics Stock Popped Nearly 4% Today | ||
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| ABIVAX | 67,70 | +0,45 % | Abivax's 580% surge hands biotech hedge funds a rare 2025 win | ||
| GERON | 1,198 | +0,08 % | Geron Corp. Posts Narrower Loss In Q1 | WASHINGTON (dpa-AFX) - Geron Corp. (GERN) posted a first quarter net loss of $19.8 million, or $0.03 per share, compared to a loss of $55.4 million, or $0.09 per share, prior year. Total net... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 4,870 | +3,84 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and... ► Artikel lesen | |
| GALAPAGOS NV | 26,840 | -0,37 % | Galapagos NV: Galapagos Creates New Subscription Right Plan | Mechelen, Belgium; August 7, 2025, 22.01
CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,800,000 subscription rights under... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,830 | +0,99 % | Cardiff Oncology, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| CENTOGENE | 0,111 | +0,91 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 0,260 | 0,00 % | Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | - Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,028 | +2,77 % | Coherus Oncology, Inc.: Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 - - Data readouts for CHS-114 and casdozokitug on track for 1H 2026 - - Q2 2025 ending cash, cash equivalents and marketable... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 1,701 | -2,47 % | CytomX: Wie geht's hier jetzt weiter? | Die Immuntherapie gegen Krebs entwickelt sich stetig weiter, und CytomX Therapeutics gehört zu den Unternehmen, die mit innovativen Ansätzen neue Maßstäbe setzen wollen. Die sogenannte "Probody"-Technologie... ► Artikel lesen |
IMAGENEBIO INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +3,71 % bei einem Aktienkurs von 13,960 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMAGENEBIO INC finden Sie auf Wallstreet Online.